Liquidia Shares Climb After First Commercial Shipment of YUTREPIA
02 Junho 2025 - 11:12AM
IH Market News
Liquidia Technologies Inc (NASDAQ:LQDA) saw its shares rise
nearly 10% following news that it will begin its initial commercial
shipments of YUTREPIA
(treprostinil) inhalation powder. This milestone follows FDA
approval granted on May 23, 2025, for the treatment of pulmonary
arterial hypertension (PAH) and pulmonary hypertension linked to
interstitial lung disease (PH-ILD). The product will soon be
accessible to patients through specialty pharmacies.
The strong market reaction reflects Liquidia’s swift efforts to
launch YUTREPIA, including rapid listing with major compendia and
distribution to specialty pharmacies within just five business days
post-approval. This quick rollout follows a favorable legal
outcome, where the U.S. District Court for the Middle District of
North Carolina rejected United Therapeutics’ (NASDAQ:UTHR) attempt
to block Liquidia’s commercialization through a preliminary
injunction and restraining order.
Liquidia CEO Dr. Roger Jeffs highlighted the company’s rapid
execution, noting, “We have moved with exceptional speed to provide
a new and differentiated therapeutic alternative to the
marketplace. In just over one week, our sales force hit the ground
running with the promotion of YUTREPIA, the product was listed with
compendia, and commercial product was shipped to specialty
pharmacies.”
The court’s decision significantly reduces legal uncertainty for
Liquidia, as it found United Therapeutics unlikely to prevail on
its patent infringement claims. This ruling paves the way for
Liquidia to proceed with the full commercial launch of
YUTREPIA.
Investor enthusiasm is buoyed by Liquidia’s ability to overcome
regulatory and legal hurdles quickly, boosting confidence in
YUTREPIA’s prospects as a leading treatment option for patients
suffering from PAH and PH-ILD. The stock’s upward movement today
highlights the importance of timely product launches and favorable
legal outcomes in influencing market sentiment.
Liquidia Technologies stock price
United Therapeutics (NASDAQ:UTHR)
Gráfico Histórico do Ativo
De Jun 2025 até Jul 2025
United Therapeutics (NASDAQ:UTHR)
Gráfico Histórico do Ativo
De Jul 2024 até Jul 2025
